Marcello Deraco

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi Morbidity and quality of life following cytoreduction and HIPEC
    M Deraco
    Department of Surgery, National Cancer Institute, Milano, Italy
    Cancer Treat Res 134:403-18. 2007
  2. ncbi The eligibility for local-regional treatment of peritoneal surface malignancy
    Vic J Verwaal
    Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Surg Oncol 98:220-3. 2008
  3. ncbi The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Marcello Deraco
    Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
    Ann Surg Oncol 20:1093-100. 2013
  4. ncbi Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study
    M Deraco
    Peritoneal Surface Malignancy Program, Department of Surgery, National Cancer Institute, Milan, Italy
    BJOG 119:800-9. 2012
  5. ncbi Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei
    Marcello Deraco
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy
    Tumori 88:370-5. 2002
  6. ncbi Management of peritoneal surface component of ovarian cancer
    Marcello Deraco
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1 20133, Milano, Italy
    Surg Oncol Clin N Am 12:561-83. 2003
  7. ncbi Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei
    Marcello Deraco
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy
    Ann Surg Oncol 11:393-8. 2004
  8. ncbi Consensus statement on peritoneal mesothelioma
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    J Surg Oncol 98:268-72. 2008
  9. ncbi Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    In Vivo 20:773-6. 2006
  10. ncbi An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma
    M Deraco
    Dept of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Exp Clin Cancer Res 22:41-5. 2003

Collaborators

Detail Information

Publications78

  1. ncbi Morbidity and quality of life following cytoreduction and HIPEC
    M Deraco
    Department of Surgery, National Cancer Institute, Milano, Italy
    Cancer Treat Res 134:403-18. 2007
  2. ncbi The eligibility for local-regional treatment of peritoneal surface malignancy
    Vic J Verwaal
    Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Surg Oncol 98:220-3. 2008
    ..General conflicting points concerning the eligibility to the local-regional therapy were discussed and voted...
  3. ncbi The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Marcello Deraco
    Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
    Ann Surg Oncol 20:1093-100. 2013
    ....
  4. ncbi Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study
    M Deraco
    Peritoneal Surface Malignancy Program, Department of Surgery, National Cancer Institute, Milan, Italy
    BJOG 119:800-9. 2012
    ..To assess the efficacy and morbidity and mortality of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer (EOC)...
  5. ncbi Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei
    Marcello Deraco
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy
    Tumori 88:370-5. 2002
    ....
  6. ncbi Management of peritoneal surface component of ovarian cancer
    Marcello Deraco
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1 20133, Milano, Italy
    Surg Oncol Clin N Am 12:561-83. 2003
    ..The indication for second-line treatment is macroscopic residual or relapse within 6 months after the completion of first line chemotherapy...
  7. ncbi Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei
    Marcello Deraco
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy
    Ann Surg Oncol 11:393-8. 2004
    ..The aim of this multicentric study was to evaluate the survival, morbidity, toxicity, and mortality of patients with PMP treated by cytoreductive surgery (CRS) with intraperitoneal hyperthermic perfusion (IPHP)...
  8. ncbi Consensus statement on peritoneal mesothelioma
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    J Surg Oncol 98:268-72. 2008
    ..The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined...
  9. ncbi Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    In Vivo 20:773-6. 2006
    ..Encouraging results have been recently reported with the combination of cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC)...
  10. ncbi An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma
    M Deraco
    Dept of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Exp Clin Cancer Res 22:41-5. 2003
    ..CRS + IPHP was proven to be acceptable in terms of morbidity and mortality in patients with PM and suggest a positive impact on outcome. Further prospective controlled studies are warranted to confirm these results...
  11. ncbi An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei
    M Deraco
    Dept of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan Italy
    J Exp Clin Cancer Res 22:35-9. 2003
    ..CRS associated with IPHP permitted complete tumour removal with an acceptable morbidity and mortality in patients with PMP. This study confirms the efficacy of the combined treatment on long-term survival and local disease control...
  12. ncbi Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion
    Marcello Deraco
    Department of Surgery, National Cancer Institute of Milan, Milan, Italy
    J Surg Oncol 83:147-53. 2003
    ..Peritoneal mesothelioma (PM) is a rare disease, with a poor prognosis. We decided to prospectively evaluate the prognostic impact of aggressive surgery followed by intraperitoneal chemotherapy with local hyperthermia...
  13. ncbi Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies
    Marcello Deraco
    Department of Surgery, National Cancer Institute of Milan, Milan, Italy
    J Surg Oncol 100:321-8. 2009
    ..The present article critically analyzes the relevant modifications from the original technique emerged during a 15-year experience in a single center. Operative outcome results are presented...
  14. ncbi [Updated treatment of peritoneal carcinomas: a review]
    M Deraco
    Dipartimento di Chirurgia, Unità Tumori Peritoneali, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano
    Minerva Chir 62:459-76. 2007
    ....
  15. ncbi Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer
    M Deraco
    Department of Surgery, Peritoneal Surface Malignancies Branch, National Cancer Institute, Via Venezian no 1, Milan, Italy
    Eur J Surg Oncol 37:4-9. 2011
    ..Several prospective phase II and III trials have recently been launched to validate the role of the combined treatment in various time points of disease natural evolution...
  16. ncbi Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial
    Marcello Deraco
    Peritoneal Surface Malignancy Program, Department of Surgery, National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
    Gynecol Oncol 122:215-20. 2011
    ..Secondary end-points were treatment morbi-mortality and outcome effects of time to subsequent adjuvant systemic chemotherapy (TTC)...
  17. ncbi Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133, Milan, Italy
    Ann Surg Oncol 13:229-37. 2006
    ..We performed a prognostic analysis in a cohort of DMPM patients treated homogeneously by cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP)...
  18. ncbi Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 15:526-34. 2008
    ..We reviewed our 10-year monoinstitutional case series to identify selection factors predicting postoperative outcome...
  19. ncbi Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity
    Shigeki Kusamura
    Department of Surgery, National Cancer Institute of Milan, Via Venezian 1, 20133, Milano, Italy
    Ann Surg Oncol 14:2550-8. 2007
    ....
  20. ncbi Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Shigeki Kusamura
    Dept of Surgery, National Cancer Institute of Milan, Milan, Italy
    Ann Surg Oncol 14:3443-52. 2007
    ..The purpose of this study was to analyze the postoperative pancreatic morbidity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies (PSM)...
  21. ncbi Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:2300-8. 2007
    ..The selection factors predicting clinical outcome are still a matter of clinical investigation. We assessed the prognostic reliability of serum tumor markers in a large series of patients with PMP undergoing CRS and HIPEC...
  22. ncbi Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique
    Shigeki Kusamura
    Department of Surgery, National Cancer Institute of Milan, Milan, Italy
    Cancer 106:1144-53. 2006
    ..Ten patients presented with Grade 3 to 4 toxicity. CONCLUSIONS: CRS + IPHP presented acceptable morbidity, toxicity, and mortality rates, all of which support prospective Phase III clinical trials...
  23. ncbi Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Dario Baratti
    Peritoneal Malignancy Program, Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 17:3220-8. 2010
    ..We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)...
  24. ncbi Colobronchial fistula: an unusual complication after peritonectomy and hyperthermic intra-peritoneal chemotherapy (HIPEC)
    Barbara Laterza
    Department of Surgery, National Cancer Institute, Milan, Italy
    In Vivo 23:151-3. 2009
    ..Due to the complexity of the combined procedure, high rates of potentially life-threatening complications have been reported. This is the first report of colobronchial fistula following CRS and HIPEC...
  25. ncbi Lymph node metastases in diffuse malignant peritoneal mesothelioma
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 17:45-53. 2010
    ..The significance of lymph node involvement in this disease is still poorly understood...
  26. ncbi Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres
    Shigeki Kusamura
    Peritoneal Surface Malignancy Program, Department of Surgery, National Cancer Institute, Milan, Italy
    J Surg Oncol 107:312-9. 2013
    ....
  27. ncbi Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg 256:334-41. 2012
    ....
  28. ncbi Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Departments of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg 249:243-9. 2009
    ..To investigate outcome and prognostic factors in patients with pesudomyxoma peritonei (PMP) treated by complete cytoreduction and hyperthermic intraperitoneal chemotherapy...
  29. ncbi Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies
    Shigeki Kusamura
    Department of Surgery, Peritoneal Surface Malignancy Program, National Cancer Institute, Milan, Italy
    Ann Surg 255:348-56. 2012
    ..To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM)...
  30. ncbi Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution
    Daisuke Nonaka
    Department of Pathology, National Cancer Institute, Milan, Italy
    Cancer 104:2181-8. 2005
    ..In the current study, the authors report the clinicopathologic features of patients with peritoneal diffuse malignant mesothelioma (DMM) who were treated in a uniform fashion at a single institution to assess prognostic factors...
  31. ncbi Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study
    Dario Baratti
    Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Ann Surg Oncol 19:1416-24. 2012
    ..Many unanswered questions remain regarding the surgical options in the management of DMPM. The aim of this case–control study was to assess the impact of the type and extent of parietal peritonectomy on survival and operative outcomes...
  32. ncbi Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion
    Rami Younan
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Via Venezian, 1, Milan, 20133, Italy
    Ann Surg Oncol 12:910-8. 2005
    ..Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors...
  33. ncbi Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma
    Barbara Laterza
    Department of Surgery, National Cancer Institute, Milan, Italy
    In Vivo 23:187-90. 2009
    ..The reliability of explorative laparoscopy (EL) in selecting patients with PM amenable to optimal combined treatment has never been specifically assessed...
  34. ncbi Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection
    Maria Rosaria Balestra
    Department of Surgery National Cancer Institute, Milan, Italy
    Tumori 96:340-4. 2010
    ..Patients infected by the human immunodeficiency virus (HIV) are still considered at a high operative risk...
  35. ncbi The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    J Surg Oncol 98:258-62. 2008
    ..Overall, 160 CP were identified. A consensus >or=51% of voters favoring one option was reached in 143/160 CP (89.4%). The general treatment guidelines and future investigational perspectives were defined...
  36. ncbi Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy
    Shigeki Kusamura
    Department of Surgery, National Cancer Institute of Milan, Italy
    J Surg Oncol 98:247-52. 2008
    ..Conflicting points concerning drugs, carrier solution and optimal temperature for hyperthermic intraperitoneal chemotherapy (HIPEC) were discussed...
  37. ncbi Technical aspects of cytoreductive surgery
    Shigeki Kusamura
    Department of Surgery, National Cancer Institute of Milan, Milan, Italy
    J Surg Oncol 98:232-6. 2008
    ..Finally when considering the place for protective ostomies the experts voted for a flexible approach allowing the surgeon to exercise discretion for individual patients...
  38. ncbi The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy
    Shigeki Kusamura
    Department of Surgery, National Cancer Institute of Milan, Milan, Italy
    J Surg Oncol 98:217-9. 2008
    ..The purpose of this manuscript is to describe the organization and the methodology of the consensus statements and to interpret and discuss the implications of the most striking results...
  39. ncbi Locoregional treatment of peritoneal carcinomatosis from gastric cancer
    F Bozzetti
    Department of Surgery, Hospital of Prato, 59100 Prato, Italy
    J Surg Oncol 98:273-6. 2008
    ..The need for a large multicenter trial to confirm the benefit and risk of intraperitoneal chemotherapy was recognized by both the experts and the authors...
  40. ncbi Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    J Surg Oncol 103:822-31. 2011
    ..The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving...
  41. ncbi Experience with peritoneal mesothelioma at the Milan National Cancer Institute
    Marcello Deraco
    Marcello Deraco, Dario Baratti, Maria Rosaria Balestra, Shigeki Kusamura, Barbara Laterza, Department of Surgery, National Cancer Institute, 20133 Milan, Italy
    World J Gastrointest Oncol 2:76-84. 2010
    ..Finally, analyses of EGFR, PDGFRA and PDGFRB were performed to ascertain if deregulation of RTK could offer useful alternative therapeutic targets...
  42. ncbi Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:500-8. 2007
    ..Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with PM undergoing CRS and IPHP...
  43. ncbi Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma
    Raffaella Villa
    Department of Experimental Oncology and Surgery, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
    Clin Cancer Res 14:4134-40. 2008
    ....
  44. ncbi Pathophysiology and biology of peritoneal carcinomatosis
    Shigeki Kusamura
    Shigeki Kusamura, Dario Baratti, Barbara Laterza, Maria Rosaria Balestra, Marcello Deraco, Department of Surgery, National Cancer Institute of Milan, Via Venezian 1, 20133 Milano, Italy
    World J Gastrointest Oncol 2:12-8. 2010
    ....
  45. ncbi Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution
    Elisabetta Pennacchioli
    Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133, Milan, Italy
    Ann Surg Oncol 14:553-9. 2007
    ..To explore the prognostic impact of isolated limb perfusion (ILP) in locally advanced extremity soft tissue sarcomas (ESTS)...
  46. ncbi Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:2790-7. 2007
    ..The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings...
  47. ncbi Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study
    M Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    Tumori 87:120-6. 2001
    ..Response to second-line chemotherapy is low, with a short median survival (8.8-15 months). We investigated the effect of an aggressive approach consisting of surgery followed by intraperitoneal drug delivery and local hyperthermia...
  48. ncbi Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 16:463-72. 2009
    ..In selected patients, aggressive management of progressive disease seems worthwhile...
  49. ncbi Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, Istituto Nazionale per la Cura e lo Studio dei Tumori, Milan, Italy
    Eur J Surg Oncol 36:1047-53. 2010
    ..MCPM is an uncommon tumour with uncertain malignant potential and no current standard therapy. Additionally, poorly defined pathological and biological features of this disease were investigated...
  50. ncbi The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs
    Shigeki Kusamura
    Peritoneal Surface Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Surg Oncol Clin N Am 21:559-76. 2012
    ..This article highlights how LC and continuous monitoring of surgical performance is critical in evaluating the credibility of emerging and already established PSM centers...
  51. ncbi Advances in clinical research and management of diffuse peritoneal mesothelioma
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Milan, Italy
    Recent Results Cancer Res 169:137-55. 2007
  52. ncbi Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan
    F Raspagliesi
    Department of Surgery-Gynaecology Unit, National Cancer Institute of Milan, Milan, Italy
    Eur J Surg Oncol 32:671-5. 2006
    ..4 and 23.9 months, respectively. The morbidity, toxicity and mortality rates were 5%, 15% and 0%, respectively. CONCLUSION: Our results suggest that CRS + IPHP merits further evaluation by a formal prospective trial...
  53. ncbi Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Dario Baratti, Shigeki Kusamura, Barbara Laterza, Maria Rosaria Balestra, Marcello Deraco, Department of Surgery, National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
    World J Gastrointest Oncol 2:36-43. 2010
    ..Current results on follow-up investigations are presented...
  54. ncbi Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma
    Nadia Zaffaroni
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
    Cell Oncol 29:453-66. 2007
    ....
  55. ncbi Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133 Milan, Italy
    Eur J Surg Oncol 36:463-9. 2010
    ....
  56. ncbi Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasiblity study
    S Kusamura
    Department of Gynecologic Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Chemother 16:19-22. 2004
    ..Six patients presented disease progression. CRS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials...
  57. ncbi Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique
    S Kusamura
    Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan
    J Exp Clin Cancer Res 22:207-12. 2003
    ..Operative mortality rate was 0.6%. CONCLUSIONS: CRS+ IPHP presented acceptable morbidity 3/4 toxicity and mortality rates what support the need to be tested in prospective phase III clinical trial...
  58. ncbi Peritoneal carcinomatosis: feature of dissemination. A review
    M Deraco
    Division of General Surgery B, Istituto Nazionale Tumori, Milan, Italy
    Tumori 85:1-5. 1999
    ....
  59. ncbi Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    In Vivo 22:153-7. 2008
    ..Here, we review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of MPM...
  60. ncbi Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer
    M Vaglini
    Istituto Nazionale per lo Studio e.la Cura dei Tumori, Milan, Italy
    Tumori 82:459-62. 1996
    ..In conclusion, isolated pelvic perfusion is useful in inoperable disease of the pelvis by reliably relieving pain and thereby improving the patients quality of life...
  61. ncbi Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach
    F Bozzetti
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 84:483-8. 1998
    ..Hyperthermic chemotherapy should be considered a promising approach in limited or impending peritoneal carcinomatosis, and should be included in the multidisciplinary approach to the treatment of locally advanced gastric cancer...
  62. ncbi Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO)
    F Di Filippo
    Department of Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy
    In Vivo 23:363-7. 2009
    ..The aim of this paper is to report on the results obtained in 75 patients with limb-threatening STS treated with a low TNFalpha dose and doxorubicin (Dx)...
  63. ncbi Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan
    M Santinami
    Division of Surgical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 82:579-84. 1996
    ..Furthermore, rHu TNF-alpha and melphalan confirmed their antitumor activity when associated with hyperthermia. Amputation or disarticulation may be reliable as a second-choice treatment for these patients...
  64. ncbi Significance of duplex/colour Doppler sonography in hepatic arterial chemotherapy for patients with liver metastases from colorectal carcinoma
    S Guadagni
    Department of Surgery, University of L Aquila, Italy
    Eur J Surg Oncol 26:381-6. 2000
    ....
  65. ncbi Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer
    S Guadagni
    Department of Surgery, University of L Aquila, L Aquila, Italy
    Arch Surg 136:105-12. 2001
    ....
  66. ncbi Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study
    Stefano Guadagni
    Department of Surgical Sciences, University of L Aquila, L Aquila, Italy
    Melanoma Res 13:51-8. 2003
    ..Further studies are necessary to establish whether the response rates can be improved by using different drug regimens...
  67. ncbi Stop Flow in abdominal and pelvic cancer relapses
    Rosario Vincenzo Iaffaioli
    Med Onc B INT Naples, Cagliari University, Italy
    Front Biosci 11:1284-8. 2006
    ..Stop-Flow is a safe and feasible technique very useful as a palliation treatment...
  68. ncbi Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion
    Olivier Glehen
    Department of Oncologic Surgery, Centre Hospitalo Universitaire Lyon Sud, Pierre Benite Cedex, France
    J Surg Oncol 98:242-6. 2008
    ..Today, the best technique is the one which is routinely used and improved into each specialized institution involved in the management of peritoneal surface malignancy...
  69. ncbi Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma
    Stefano Guadagni
    Department of Surgical Sciences, University of L Aquila, 67010 L Aquila, Italy
    Am J Surg 183:28-36. 2002
    ..A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure...
  70. ncbi Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy
    Rami Younan
    Department of Surgery, Surgical Oncology Unit, University of Montreal Health Center, Montreal, Canada
    J Surg Oncol 98:253-7. 2008
    ..A related document was sent to an international panel of experts. The CTCAE was adopted by the panel of experts as the unique classification system to be used for reporting complications related to CRS + HIPEC...
  71. ncbi Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination
    Jesus Esquivel
    Surgical Oncology, St Agnes Hospital, Baltimore, Maryland 21229, USA
    J Surg Oncol 98:263-7. 2008
    ..This manuscript will analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients...
  72. ncbi Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study
    Carlo R Rossi
    Dipartimento di Scienze Oncologiche e Chirurgiche, Sezione Clinica Chirurgica Generale II, Universita di Padova, Italy
    Cancer 94:492-9. 2002
    ..To evaluate whether this regimen could be used for other tumor types, the authors conducted a Phase I study on HIIC with doxorubicin and cisplatin in patients with peritoneal carcinomatosis or sarcomatosis...
  73. ncbi Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients
    Carlo Riccardo Rossi
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padua, Italy
    Cancer 100:1943-50. 2004
    ..After a Phase I study on cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (HIIC), the authors reported the results of the treatment of 60 patients using this novel multimodal approach...
  74. ncbi Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)
    Brendan Moran
    Colorectal Research Unit, North Hampshire Hospital, Basingstoke, Hampshire, UK
    J Surg Oncol 98:277-82. 2008
    ..Concerning the main controversial methodological questions, there was an high grade of consistency among the experts and agreement with the findings of the literature...
  75. ncbi Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer
    C William Helm
    Division of Gynecologic Oncology, James Graham Brown Cancer Center, University of Louisville, Kentucky 40207, USA
    J Surg Oncol 98:283-90. 2008
    ....
  76. ncbi The consensus statement on the locoregional treatment of abdominal sarcomatosis
    Carlo Riccardo Rossi
    Sarcoma and Melanoma Unit, Clinica Chirurgica II, University of Padova Italy
    J Surg Oncol 98:291-4. 2008
    ..A questionnaire was placed on the website of the 5th International Workshop on Peritoneal Surface Malignancy and the experts voted via internet...
  77. ncbi Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin
    Gaetano La Manna
    Nephrology, Dialysis and Renal Transplant Unit, University of Bologna, St Orsola Hospital, Italy
    In Vivo 20:703-6. 2006
    ..This finding suggests that the higher the protein reduction is, the lower the e-GFR determination is at three months...
  78. ncbi Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy
    Santiago Gonzalez-Moreno
    Department of Surgical Oncology, Peritoneal Surface Oncology Program, Centro Oncológico MD Anderson International España, Madrid, Spain
    J Surg Oncol 98:237-41. 2008
    ..However, a uniform assessment method and categorization for this paramount prognostic indicator is lacking...